Jump to content

User:Mr. Ibrahem/Nirmatrelvir/ritonavir

From Wikipedia, the free encyclopedia
< User:Mr. Ibrahem

This is an old revision of this page, as edited by Mr. Ibrahem (talk | contribs) at 22:17, 25 January 2022 (from https://mdwiki.org/wiki/Nirmatrelvir/ritonavir). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Mr. Ibrahem/Nirmatrelvir/ritonavir
Combination of
NirmatrelvirAntiviral drug
RitonavirAntiviral drug
Clinical data
Trade namesPaxlovid
License data
Routes of
administration		By mouth
Legal status
Legal status

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is two medications packaged together and used to treat COVID-19.[1] It is used within 5 days of the start of symptoms, in people who do not require supplemental oxygen, but are at high risk of developing severe COVID-19.[1][3] It is taken by mouth.[3]

Common side effects include taste disturbances, diarrhea, high blood pressure, and muscle pains.[3] Safety in pregnancy is unclear.[1] It should not be used in people with severe liver or kidney problems.[1] It has a number of medication interactions, including with hormonal birth control.[3][1] It is contains nirmatrelvir, a SARS-CoV-2 main protease inhibitor and ritonavir, a CYP3A inhibitor.[3]

The combination was approved for medical use in the United Kingdom in December of 2021.[1] It also received emergency use authorization in the United States that month.[3] In 2021 the United States government bought 10 million courses of treatment at 530 USD each, which it will be providing at no cost to Americans.[6][7]

References

  1. ^ a b c d e f g h i "Summary of Product Characteristics for Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Retrieved 31 December 2021.
  2. ^ "Regulatory approval of Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Retrieved 31 December 2021.
  3. ^ a b c d e f g h i j "Paxlovid- nirmatrelvir and ritonavir kit". DailyMed. Retrieved 30 December 2021.
  4. ^ "FDA Authorizes First Oral Antiviral for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 22 December 2021. Retrieved 22 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid (PDF) (Technical report). Pfizer. 22 December 2021. LAB-1492-0.8. Archived from the original on 23 December 2021.
  6. ^ "U.S. to buy 10 mln courses of Pfizer's COVID-19 pill for $5.3 bln". Reuters. 18 November 2021. Retrieved 6 January 2022.
  7. ^ "FDA Grants Pfizer's COVID Antiviral Pill EUA - GoodRx". GoodRx. Retrieved 6 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Nirmatrelvir/ritonavir&oldid=1067934457"